Interferon in the treatment of cutaneous T-cell lymphoma
2003; Wiley; Volume: 16; Issue: 4 Linguagem: Inglês
10.1111/j.1396-0296.2003.01643.x
ISSN1529-8019
Autores Tópico(s)Lymphoma Diagnosis and Treatment
ResumoInterferons are polypeptides with a broad range of in vivo effects that have shown efficacy in cutaneous T-cell lymphoma (CTCL). Particularly useful is alfa interferon (IFN) which, as a single agent, has shown partial remission rates of > 50% and complete responses of > 20%. Side-effects are predictable, generally well tolerated and dose-related. The efficacy of IFN has increased with combination therapy without any significant increase in attendant side-effects. An update on the specifics of the different IFN subtypes, their inherent biologic activity, pharmacokinetics, efficacy and safety in CTCL is presented in this paper.
Referência(s)